
View larger version (16K):
[in this window]
[in a new window]
|
Fig. 2. KaplanMeier estimates of disease-free survival (DFS). A) DFS according to AIB1 expression for patients who did not receive adjuvant therapy (n = 119). Patients with high AIB1 expression (top quartile: AIB1>1.67 densitometric units) were compared with patients with lower AIB1 expression ( 1.67 densitometric units). B) DFS curves for patients who did not receive adjuvant therapy (n = 119). Patients with high AIB1 expression (top quartile) and low HER-2 expression were compared with patients with high expression of both AIB1 and HER-2, low expression of both AIB1 and HER-2, or low AIB1 expression and high HER-2 expression. C) DFS for patients who received adjuvant tamoxifen therapy (n = 187). Patients with high AIB1 expression (top quartile) and high HER-2 expression (grades 24) were compared with patients with high expression of both AIB1 and HER-2, low expression of both AIB1 and HER-2, or low AIB1 expression and high HER-2 expression. All P values refer to two-sided log-rank tests. Numbers below each graph indicate the number of patients remaining at risk in each group. Vertical lines are the 95% confidence intervals at selected time points.
|